NASDAQ · COR
Healthcare · Medical - Distribution
$323.85
Up+$2.50 (+0.78%)
Updated Oct 10, 2026, 8:09 PM
SID Score
5.6/10
Composite research score
Smart Money
50/100
Neutral
Price performance · COR
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
COR closed at $323.85 after 21 trading sessions, up 0.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $319.50 | $325.82 | $318.79 | $323.85 | 781.95K |
| Oct 8, 2026 | $316.59 | $322.58 | $314.90 | $321.35 | 897.58K |
| Oct 7, 2026 | $317.30 | $322.41 | $315.15 | $317.25 | 1.06M |
| Oct 6, 2026 | $314.63 | $316.44 | $311.83 | $316.37 | 817.91K |
| Oct 5, 2026 | $309.43 | $316.06 | $307.87 | $314.93 | 1.15M |
| Oct 2, 2026 | $308.29 | $310.425 | $302.14 | $309.05 | 1.16M |
| Oct 1, 2026 | $303.18 | $313.02 | $300.77 | $309.78 | 1.89M |
| Sep 30, 2026 | $306.40 | $306.40 | $295.01 | $300.25 | 1.81M |
| Sep 29, 2026 | $300.00 | $307.62 | $298.21 | $307.60 | 1.27M |
| Sep 28, 2026 | $306.20 | $307.94 | $302.84 | $303.81 | 1.52M |
| Sep 25, 2026 | $308.95 | $310.89 | $304.31 | $306.92 | 1.08M |
| Sep 24, 2026 | $313.32 | $316.61 | $309.18 | $309.87 | 1.08M |
| Sep 23, 2026 | $315.51 | $320.24 | $310.705 | $312.28 | 1.1M |
| Sep 22, 2026 | $317.62 | $320.00 | $313.89 | $314.43 | 775.72K |
| Sep 21, 2026 | $309.74 | $316.98 | $308.51 | $316.49 | 1.05M |
| Sep 18, 2026 | $307.42 | $311.81 | $304.45 | $308.78 | 3.34M |
| Sep 17, 2026 | $318.36 | $319.765 | $309.24 | $309.41 | 1.1M |
| Sep 16, 2026 | $321.83 | $323.98 | $317.97 | $318.50 | 931.14K |
| Sep 15, 2026 | $324.98 | $325.875 | $318.08 | $323.29 | 913.5K |
| Sep 14, 2026 | $325.64 | $327.79 | $322.46 | $326.23 | 1.06M |
| Sep 11, 2026 | $323.99 | $325.125 | $317.96 | $321.57 | 844.06K |
The latest Smart Investors Daily articles mentioning COR.
Company
Market Activity
Research & News
COR research
Company profile and research snapshot.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Leerink Partners | Outperform | — |
| Sep 8, 2026 | RBC Capital | Sector Perform | — |
| Aug 19, 2026 | RBC Capital | Sector Perform | — |
| Aug 11, 2026 | Wells Fargo | Overweight | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 2, 2026
CONSHOHOCKEN, Pa., October 02, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.
Benzinga · Sep 28, 2026
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.44% on an annualized basis producing an average annual return of 20.45%. Currently, Cencora has a market capitalization of $57.98 billion.
Yahoo · Sep 28, 2026
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Yahoo · Sep 25, 2026
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COR.
